AI VIVO
AI VIVO helps drug developers predict how diseases and treatments affect organs to speed discovery of new medicines. It builds OrganoMaps by combining AI models with multi‑modal omics data and a proprietary systems pharmacology platform to model organ‑level biology and treatment responses. The technology is positioned as a B2B SaaS/platform for pharmaceutical and biotechnology companies and research organizations. AI VIVO's platform supports preclinical and translational workflows to prioritize targets and interventions across organ systems.
AI VIVO
AI VIVO helps drug developers predict how diseases and treatments affect organs to speed discovery of new medicines. It builds OrganoMaps by combining AI models with multi‑modal omics data and a proprietary systems pharmacology platform to model organ‑level biology and treatment responses. The technology is positioned as a B2B SaaS/platform for pharmaceutical and biotechnology companies and research organizations. AI VIVO's platform supports preclinical and translational workflows to prioritize targets and interventions across organ systems.
TL;DR
Headquarters: Cambridge, UK (Bio‑Innovation Centre, Cambridge Science Park)
Product: AI-powered systems pharmacology platform (OrganoMaps) for modelling organ-level disease and treatment effects
Customers / Market: Pharmaceutical and biotechnology companies; research organizations (B2B SaaS/platform)
Founded: 2019
Known investor: O2h Ventures
Company Overview
Problem Domain
Drug discovery and translational research—modeling organ-level biology and treatment responses.
Founded
2019
Industry
Biotechnology
Tech Stack
Funding Track Record
Funding-related entries and multiple rounds recorded on company profiles; specific amounts obfuscated in public records.
Investor Signal
“O2h Ventures (listed as an investor/supporter); additional supporters listed on profiles include Tech Nation, Martlet, Pierre Socha, KQ Labs”